ASH HIGHLIGHTS 2023 – LYMPHOMA ROUNDTABLE DISCUSSION: Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients

2356 232